A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.
Adolescent
Adult
Antibodies, Bacterial
/ blood
Dose-Response Relationship, Immunologic
Healthy Volunteers
Humans
Immunogenicity, Vaccine
Immunoglobulin G
/ blood
Infant
Middle Aged
Pneumococcal Infections
/ prevention & control
Pneumococcal Vaccines
/ administration & dosage
Streptococcus pneumoniae
/ immunology
Vaccines, Conjugate
/ administration & dosage
Young Adult
Pneumococcal conjugate vaccine
immunogenicity
safety
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
29
1
2019
medline:
27
2
2020
entrez:
29
1
2019
Statut:
ppublish
Résumé
Two new formulations of an investigational 15-valent pneumococcal conjugate vaccine (PCV15-A and PCV15-B) were developed using 2 different protein-polysaccharide conjugation processes and evaluated in separate phase I/II studies (NCT02037984 [V114-004] and NCT02531373 [V114-005]) to assess optimal concentrations of pneumococcal polysaccharide (PnPs) and Aluminum Phosphate Adjuvant. Various lots of PCV15-A and PCV15-B containing different concentrations of PnPs and/or adjuvant were compared to PCV13 in young adults and infants. Adults received single dose and infants received 4 doses at 2, 4, 6, and 12-15 months of age. Adverse events (AEs) were collected after each dose. Serotype-specific immunoglobulin G (IgG) concentrations and opsonophagocytic activity (OPA) were measured prior and 30 days postvaccination in adults, at 1 month postdose 3 (PD3), pre-dose4, and postdose 4 (PD4) in infants. Safety profiles were comparable across vaccination groups. At PD3, serotype-specific IgG GMCs were generally lower for either PCV15 formulation than PCV13 for most shared serotypes. PCV15 consistently elicited higher antibody responses to the 2 serotypes unique to the vaccine (22F and 33F) and serotype 3 for which PCV13 was shown to be ineffective. Except for serotypes 6A and 6B, no dose-response effect was observed with increasing concentrations of PnPs and/or adjuvant. PCV15 is safe and induces IgG and OPA responses to all 15 serotypes in the vaccine. No significant differences in antibody responses were observed with increases in PnPs and/or Aluminum Phosphate Adjuvant.
Sections du résumé
BACKGROUND
Two new formulations of an investigational 15-valent pneumococcal conjugate vaccine (PCV15-A and PCV15-B) were developed using 2 different protein-polysaccharide conjugation processes and evaluated in separate phase I/II studies (NCT02037984 [V114-004] and NCT02531373 [V114-005]) to assess optimal concentrations of pneumococcal polysaccharide (PnPs) and Aluminum Phosphate Adjuvant.
METHODS
Various lots of PCV15-A and PCV15-B containing different concentrations of PnPs and/or adjuvant were compared to PCV13 in young adults and infants. Adults received single dose and infants received 4 doses at 2, 4, 6, and 12-15 months of age. Adverse events (AEs) were collected after each dose. Serotype-specific immunoglobulin G (IgG) concentrations and opsonophagocytic activity (OPA) were measured prior and 30 days postvaccination in adults, at 1 month postdose 3 (PD3), pre-dose4, and postdose 4 (PD4) in infants.
RESULTS
Safety profiles were comparable across vaccination groups. At PD3, serotype-specific IgG GMCs were generally lower for either PCV15 formulation than PCV13 for most shared serotypes. PCV15 consistently elicited higher antibody responses to the 2 serotypes unique to the vaccine (22F and 33F) and serotype 3 for which PCV13 was shown to be ineffective. Except for serotypes 6A and 6B, no dose-response effect was observed with increasing concentrations of PnPs and/or adjuvant.
CONCLUSION
PCV15 is safe and induces IgG and OPA responses to all 15 serotypes in the vaccine. No significant differences in antibody responses were observed with increases in PnPs and/or Aluminum Phosphate Adjuvant.
Identifiants
pubmed: 30689507
doi: 10.1080/21645515.2019.1568159
pmc: PMC6988874
doi:
Substances chimiques
Antibodies, Bacterial
0
Immunoglobulin G
0
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
549-559Références
Vaccine. 2018 Oct 29;36(45):6883-6891
pubmed: 30244873
Clin Microbiol Infect. 2014 May;20 Suppl 5:45-51
pubmed: 24313448
Lancet Infect Dis. 2018 Apr;18(4):441-451
pubmed: 29395999
Euro Surveill. 2015 Mar 12;20(10):21057
pubmed: 25788255
Clin Vaccine Immunol. 2006 Sep;13(9):1004-9
pubmed: 16960111
Clin Infect Dis. 2016 Sep 1;63(5):611-8
pubmed: 27225239
Lancet. 2009 Sep 12;374(9693):893-902
pubmed: 19748398
Vaccine. 2015 Jan 3;33(2):359-66
pubmed: 25448105
Vaccine. 2015 Jun 4;33(24):2793-9
pubmed: 25913828
Expert Rev Vaccines. 2013 Dec;12(12):1379-94
pubmed: 24195479
J Infect Dis. 2010 Jan 1;201(1):32-41
pubmed: 19947881
Lancet Infect Dis. 2015 Mar;15(3):301-9
pubmed: 25656600
Vaccine. 2011 Jul 12;29(31):4940-6
pubmed: 21596077
Pediatr Infect Dis J. 2015 Feb;34(2):186-94
pubmed: 25741971
Clin Infect Dis. 2019 May 30;68(12):2135-2143
pubmed: 30357326
Pediatr Infect Dis J. 1998 Mar;17(3):211-6
pubmed: 9535248
Lancet Infect Dis. 2015 May;15(5):535-43
pubmed: 25801458
Pediatrics. 1998 Nov;102(5):1087-97
pubmed: 9794939
Stat Med. 1985 Apr-Jun;4(2):213-26
pubmed: 4023479
Vaccine. 2007 Sep 4;25(36):6557-64
pubmed: 17681648
Pediatr Infect Dis J. 2005 Aug;24(8):670-5
pubmed: 16094218
Hum Vaccin Immunother. 2015;11(6):1313-22
pubmed: 25912208
Vaccine. 1999 Jun 4;17(20-21):2726-32
pubmed: 10418924
Vaccine. 2018 Oct 29;36(45):6875-6882
pubmed: 29559167
PLoS One. 2017 Aug 14;12(8):e0183191
pubmed: 28806737
J Biol Stand. 1988 Oct;16(4):275-9
pubmed: 2848843
Pediatr Infect Dis J. 2005 Aug;24(8):665-9
pubmed: 16094217
Hum Vaccin Immunother. 2014;10(1):33-9
pubmed: 24096297
Clin Infect Dis. 2017 Nov 13;65(11):1780-1789
pubmed: 29020171
Clin Vaccine Immunol. 2009 Mar;16(3):387-96
pubmed: 19158284
Vaccine. 2007 May 16;25(20):4029-37
pubmed: 17391816
Paediatr Drugs. 2008;10(2):75-83
pubmed: 18345717
Pediatrics. 2008 Feb;121(2):253-60
pubmed: 18245415